KRT18 and infection: ,35,36,37 In this study, we assessed the immunogenicity and protective efficacy of the bivalent (Original/Omicron BA.4-5) mRNA vaccine against SARS-CoV-2 XBB.1.5 breakthrough infection in K18-hACE2 transgenic mice, using various vaccination schedules.